Good end to 2025 and encouraging 2026 outlook
29/01/26 -"Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The medium-to-long-term growth should be supported by ..."
Pages
67
Language
English
Published on
29/01/26
You may also be interested by these reports :
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...
28/01/26
2025 was a year of US tariff threats and drug pricing pressure on the pharma industry, and for AstraZeneca (REDUCE; UK), it started under the cloud ...
27/01/26
Critical USA size increase with value-accretive capacity acquisition